Efficacy of entecavir-to-tenofovir switching treatment to attain a drug-free state in chronic hepatitis B: a randomized controlled trial
Not Applicable
Recruiting
- Conditions
- chronic hepatitis B
- Registration Number
- JPRN-UMIN000021793
- Lead Sponsor
- Department of Hepatology, Osaka Metropolitan University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
1. no previous use of other nucleoside analog 2. presence of resistance to nucleoside analog 3. other likely causes of chronic liver disease, such as autoimmune or alcoholic liver disease 4. viable HCC or other malignancies 5. decompensated liver function (Child B or C) 6. severe complication (ex. impaired renal, cardiac or respiratory function) 7. women who are possibly pregnant, expectant mothers, and lactating mothers 8. history of allergy to nucleoside analog
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method